TrialPath
Asthma · Washington

Asthma clinical trials in Washington

4 recruiting asthma studies within range of Washington. Click any trial for full eligibility criteria and contact info.

Registry of Asthma Characterization and Recruitment 3 (RACR3)

NCT05272241 · Asthma
Recruiting

This is a multi-center, non-interventional registry to create and maintain a database of participants to serve as a recruitment source for current and future DAIT NIAID-sponsored Childhood Asthma in Urban Settings (CAUSE) studies.

Phase—
TypeObservational
AgeAny
WhereAurora, Colorado, United States + 6 more
SponsorNational Institute of Allergy and Infectious Diseases (NIAID)
▾Tap for details

Protocol CAUSE-03 / CHEETAH

NCT06136091 · Asthma
Recruiting

This is a one-year longitudinal, observational study of 250 urban children and adolescents with asthma and 60 without asthma, ages 6-17 years old. Participants with asthma will require daily controller therapy with inhaled corticosteroids ICS (at least Step 2 therapy). Those without asthma cannot have used asthma medications in the year prior to enrollment and cannot demonstrate bronchodilator reversibility at baseline. Phenotypic characteristics will be established at baseline, and the participants will be seen at scheduled visits over 12 months. Each participant will be asked to monitor and self-report cold symptoms and will be asked to complete up to three cold visits

Phase—
TypeObservational
Age6 Years – 17 Years
WhereAurora, Colorado, United States + 7 more
SponsorNational Institute of Allergy and Infectious Diseases (NIAID)
▾Tap for details

Omalizumab Before Onset of Exacerbations

NCT05332067 · Asthma in Children, Atopy, Viral Upper Respiratory Infection
Recruiting

OBOE is a prospective, pilot, parallel group RCT with the overall aim of examining the effect of a single dose of anti-IgE (omalizumab) vs. placebo administered at the onset of URIs in the fall season among highly exacerbation-prone, urban, and atopic youth aged 6-17 years with persistent asthma. OBOE will recruit and randomize participants over 3 years (3 annual cohorts of participants). Recruitment for each of the yearly cohorts of OBOE will begin in February. Each cohort will be followed for a 2-6-month run-in period with the objective to gain control of each participant's asthma and to stabilize the required controller medication step level. Participants will receive routine asthma care every 1-2 months (a total of 2-4 times) during run-in using a previously described algorithm developed by the Inner-city Asthma Consortium and successfully employed in the PROSE study. The primary outcome is the change in the amount of nasal IFN-α recovered by nasal fluid absorption between two time points, within 72 hours of onset of a URI as defined by onset of (or substantial worsening of) rhinorrhea, nasal congestion or sneezing (single or multiple symptoms) and 3-6 days after study drug injection.

PhasePhase 2
TypeInterventional
Age6 Years – 17 Years
WhereWashington D.C., District of Columbia, United States
SponsorChildren's National Research Institute
▾Tap for details
Apply

The Exhale Study: Treating Maternal Depression in an Urban Pediatric Asthma Clinic

Recruiting

The goal of this clinical trial is to test the effectiveness and implementation of delivering Enhanced Brief Interpersonal Psychotherapy (IPT-B), an evidence-based maternal depression treatment, to mothers of children under the age of 18 in an urban pediatric asthma clinic. Researchers will compare Enhanced IPT-B and supplemented usual care (brief care coordination). The main questions the trial aims to answer are: 1. Does Enhanced IPT-B decrease maternal depressive symptoms? 2. Does Enhanced IPT-B improve child asthma management and health outcomes (exacerbations, symptoms, control)? 3. What are the preliminary implementation outcomes of delivering Enhanced IPT-B in an urban pediatric asthma clinic?

PhaseNA
TypeInterventional
AgeAny
WhereWashington D.C., District of Columbia, United States
SponsorChildren's National Research Institute
▾Tap for details
Apply